rtf icon - Ag-West Biotech Inc

Document Sample
rtf icon - Ag-West Biotech Inc Powered By Docstoc
					                                  AgBiotech Bulletin
                                Volume 1, Issue 1  June 2004
                                Published by Ag-West Bio Inc.



Presenting Ag-West Bio Inc. - a new life science organization for
Saskatchewan

Saskatchewan has huge potential for the economy of the 21st century – the bio-economy - and
Ag-West Bio Inc. is poised to lead the way!
Ag-West Biotech Inc., Bio-Products Saskatchewan Inc., and the Saskatchewan Nutraceutical
Network have joined forces to position Saskatchewan as the premiere centre for the bio-based
economy. Ag-West Bio Inc. has its roots in three highly successful economic development
agencies. Together, the strengths of each organization will be combined to bring a greater power
and synergy to our goal of building and strengthening the province‟s life science industry
providing new economic opportunities for Saskatchewan.
The official announcement of Ag-West Bio was April 30, 2004. “I am extremely proud to be
involved in the development and launch of this new organization,” said the President & CEO of
Ag-West Bio Inc., Dr. Ashley O‟Sullivan. “Saskatchewan has one of the greatest concentrations
of life science knowledge, expertise, and resources in Canada. Ag-West Bio is strategically
positioned to capture maximum value                          for Saskatchewan in the emerging
bio-economy.”
Through early stage investment in commercialization, R&D facilitation, regulatory and policy
development, building business competitiveness, communication and advocacy roles, Ag-West
Bio Inc. will focus on economic development of products derived from living organisms with
market applications in agricultural, environmental, industrial, energy and bio-processing markets
and human nutrition and health. Saskatchewan will be in the international spotlight for leadership
in the bio-economy.
“The Government of Saskatchewan is pleased to announce funding to Ag-West Bio Inc. of
$900,000 per year, for the next three years,” Saskatchewan Agriculture, Food and Rural
Revitalization Minister Mark Wartman said. “With this merger, we have taken a significant step
forward toward the creation of a leading edge, bio-based economy that combines agricultural
science and technology, health and nutrition, bio-energy, bio-products and bio-processing to
create new economic opportunities and jobs for Saskatchewan.”

Dr. Ashley O’Sullivan will lead the strategic management of the Ag-West Bio team, as well as
business development within the agricultural sector. Ron Kehrig, the Vice President,
BioProducts and BioProcesses, will be responsible for business development in the bio-products,
bio-processes and environmental sectors and Dr. Carol Ann Patterson, the Vice President,
Nutrition and Health, will manage the natural health products and functional foods sectors.
Together, this team combines knowledge, expertise, and experience to provide one door to
Saskatchewan’s future growth in the bio-economy.
To support Saskatchewan‟s agricultural biotechnology industry, we will continue to
communicate sector issues, trends and opportunities to stakeholders, government and the general
public through the production of the AgBiotech Bulletin. This publication will now arrive four
times a year as opposed to monthly. Two other quarterly publications are being introduced – the
NutraNews, (a former SNN publication) covering nutrition and health sectors and Bio-Prospects,
following bio-products and bio-processes industries.
To sign up for a free subscription to any of these publications, please fax your requests to:
306-975-1966, e-mail: subscriptions@agwest.sk.ca, or visit: http://www.agwest.sk.ca



Audiences heard an International Perspective on GM Crops at Co-
Existence: the Challenges and Opportunities
Despite the debate, global acreages of both GM and organic crops are increasing. A formula to
achieve co-existence between these diverse markets must be found. Approximately 100 delegates
and speakers from across the globe came to the Co-Existence: The Challenges and Opportunities
conference in Saskatoon, May 16 to 17, to discuss these challenges and opportunities.

Speakers at the opening plenary session gave an in-depth view of the European perspective,
starting with Graham Brookes, Director of PG Economics. Graham‟s report - Co-Existence of
GM and non GM arable crops: the non GM and organic context in the EU – was just released
and we had the opportunity to be among the first to have a personal overview.

At a birds eye view, the scope of European situation – in an economics perspective - was
immediately evident. For genetically modified crops, actual market values show the demand for
non GM soy and corn to be relatively low at 27% and 36% of the total soy and corn demand
respectively. The majority of this demand is in food markets.

Organic crop production, on the other hand, accounts for only 3-5% of the total crop production
and of that 90% is grassland. The main reason for this is labor intensive weed control, high
nutrient requirements, and high production risks. Demand is also low when viewed on a large
scale level. Therefore, is the European market really demanding GM free?

In the only real EU example of co-existence, Graham outlined the experience in Spain.
Conventional corn still dominates the market with 92.8% but GM corn (Bt) is growing. In 2003,
32,000 hectares were grown (7%) and this is expected to increase. Graham predicted 2004 could
see 50,000 hectares planted to Bt corn. Organic growers accounted for less than 0.2% of the total
corn hectares grown.

In his opinion, co-existence in Spain has succeeded. “Only two isolated instances of GM
presence in organic crops have been cited and there was a lack of data to support their claim,”
said Graham. “The likely cause of these was the use of non-certified GM free seed by growers.”
Co-existence is only an issue if a non-GM crops are sold into a market where GM status is
important and this is a small part of the market and is likely to decline.
He was also quick to note that liability issues around co-existence are a two-way street. “Weed
seeds and organic pollen with old, poor quality traits can flow into conventional farmer‟s fields
contaminating their high quality seed traits.”

Graham also gave us a sneak preview into his newest report on co-existence within North
America, to be released at BIO 2004 in San Francisco. Organic acreages are growing in the
United States and Canada but the total acreages are still extremely low. GM crops on the other
hand account for approximately 60% of the total area of soy, corn and canola grown and again,
they have co-existed for several years now without significant economic problems. He uses the
example of North American farmers growing specialized crops, Nexera canola for example, for
many years without compromising purity level. Keep your eyes open for the full report.

The next speaker, Dr. Stephen Preusser, Business Development Officer of the Department of
Foreign Affairs and International Trade, gave a very interesting perspective of the political
debate over GM legislation in the EU and Germany, in particular.

German Minster Künast, who uses her influence to halt the proliferation of GM crops, is the
same Minister who was responsible to produce the proposed law implementing the EU white
paper permitting the cultivation of GM crops. The law her office proposed will create such a
personal liability issue, farmers will be discouraged from growing GM crops.

In detail, the proposed law states if doubts exist about the risks to either the environment or
health, protective measures can be undertaken even when no evidence exisits concerning either
the presence or the gravity of a risk. Also, if the level of adventitious GM pollen causes a
financial loss, neighboring farmers growing GM crops can be liable even with no burden of
proof. To aid farmers who might still desire to grow GM crops, even though they could be
placed in a very tight legal situation, a “Good Agricultural Practice” guidelines is to be produced,
but it could come out 3 to 4 months after the law.

The response to this proposed law has not been positive by any interested party. Environmental
groups oppose the draft law because fines and liabilities are set too low, separation distances are
too small (although none have actually been determined), and there are no GM free zones.
Farmers Associations are opposed due to the open-ended liability issue and industry feels the
liability is too restrictive. The Upper House of government is opposed on three main areas –
regulations, liability, and choice of government agency to carry out registration and evaluation
tests. They have suggested over 100 changes to a law that is only 22 pages long.

What will happen next? As no agreement between the upper and lower houses of government is
foreseeable, the law will have to go to a committee for mediation. “The result,” according to
Stephen, “is Minister Künast will have to make many painful concessions and it could be some
time before the issue is settled.”

Dr. Clive James, Chair of the International Service for the Acquisition of Agri-biotech
Applications (ISAAA) Board of Directors, closed the session with an international perspective of
GM crops and their contribution to sustainability and the future.
“In the next 50 years, man will consume double the food he has consumed since the beginning of
agriculture, … we have the onerous duty to bring this challenge to society,” Clive stated. “GM
crops are not the panacea, but can be an essential part of the solution. We need to take the best of
conventional technology with the best of biotechnology to feed the world.”

Farmers worldwide are realizing the benefits of biotechnology. Global acreages of transgenic
crops are growing rapidly with the most rapid adoption by resource-poor farmers in developing
countries. Clive predicts double digit growth rates over the next 5 years.

When asked if the resource poor farmers should have to pay for the technology, Clive relates an
example of a farmer in South Africa who purchased Bt cotton seed. “She is female, as are most
of the farmers in S. Africa. Bt cotton saved her 12 days of labor spraying her fields. She walked
100 fewer kilometers. She was able to use those 12 days caring for the sick, as S. Africa is
plagued with Aids, and she made more money per hectare of crop. Money needed to feed her
family. This is an example of how biotechnology contributes to the alleviation of poverty.”

More Resources:
Co-Existence of GM and non GM arable crops: the non GM and organic context in the EU
http://www.pgeconomics.co.uk
International Service for the Acquisition of Agri-Biotech Applications http://www.isaaa.org


Regulatory
‘David versus Goliath’ or ‘David versus Davids’
Canadian Regulations, with respect to intellectual property protection, is out of step with the rest
of the world but the recent decision by the Supreme Court of Canada in favor of Monsanto
against Percy Schmeiser will go a long way to encourage innovation in this country.

In this court case, patenting higher life forms was potentially an important issue and, although
the court ruled in favor of Monsanto, it avoided dealing directly with the issue. According to
official court transcripts, the judges ruled, “The patent is valid. The respondents did not claim
protection for the genetically modified plant itself, but rather for the genes and the modified cells
that make up the plant. A purposive construction of the patent claims recognizes that the
invention will be practiced in plants regenerated from the patented cells, whether the plants are
located inside or outside a laboratory. Whether or not patent protection for the gene and the cell
extends to activities involving the plant is not relevant to the patent's validity. The appellants
have failed to discharge the onus to show that the Commissioner of Patents erred in allowing the
patent.”

Dr. Konrad Sechley, a Partner and patent agent with Gowling Lafleur Henderson LLP, reviewed
the status of higher life forms in Canada, Europe, and the United States at the recent Co-
existence: the Challenges and Opportunities conference in Saskatoon. According to him,
wording of the law is very open to interpretation. For example, the Canadian definition of
invention – “invention means any new and useful art, process, machine, manufacture, or
composition of matter, or any new and useful improvement in any art, process, machine,
manufacture or composition of matter” - is almost identical to the United States‟ definition. Yet
the two countries have very different interpretations.

A prime example lies in the Harvard mouse. Harvard University submitted a patent for a
transgenic mouse containing an „oncogene‟. Through the definition of invention, the US Courts
allowed the patent. Canada, on the other hand, through its interpretation of the definition of
invention concluded that higher life forms are not patentable. Interestingly, the European Patent
Office also ruled in favor of Harvard allowing the „oncomouse‟ to be patented in Europe.

So what is the relevance to Canadians? Biotechnology research and development in Canada
represents a very important aspect of the Canadian economy with over $1 billion dollars invested
in 2001 alone. And these research dollars do not only relate to an increased value to the Canadian
GDP, but also to increased job opportunities. In 2000, 62,242 people were employed in
biotechnology-related companies, 70% of which are small (under 20 employees) and cannot
afford increased impediments to bringing their products to market. These small companies are
the ‟Davids‟ who stood to gain or lose the most depending on the outcome of this case.

So, in the words of Dr. Ashley O‟Sullivan, President & CEO of Ag-West Bio, “The battle
between Percy Schmeiser and Monsanto was not a case of David versus Goliath but rather David
versus Davids.” Thank goodness the right Davids won!

Source:
Mighty Maples from Little Saplings Grow: A Working Paper for a Strategic Partnership with Canadian
Biotechnology, December 2003
http://www.biotech.ca/PDFs/Finance%20Poistion%20Paper_Mighty%20Maples_Dec03.pdf



Innovation

Poultry Vaccines – an ounce of prevention worth a pound of cure
By Eileen Dent, MSc, MBA

Canadian consumers are acutely aware of the dangers of food pathogens due to high-profile
cases of mad cow disease and the avian flu. Although British Columbia farmers affected by the
avian flu will receive three million dollars in aid from the Chicken Farmers of Canada, the
national farmer-run organization acknowledges that this assistance will not cover producers‟
expected losses.

Producers are therefore eager to invest in any technology that will minimize the risk of another
economically devastating food safety scare.
That‟s why Dr. Brenda Allan of Saskatoon‟s Vaccine & Infectious Disease Organization (VIDO)
is working with producers like the Alberta Livestock Industry to develop a vaccine against
Campylobacter jejuni, a human pathogen found in poultry.

Campylobacter rapidly colonizes entire flocks of birds without provoking any symptoms. It is
estimated that between thirty and one hundred percent of poultry from any given flock carry the
bacteria. Although Campylobacter is harmless to poultry, it causes people to become seriously
ill. “Campylobacter causes gastroenteritis; it produces toxins that cause severe diarrhoea,” said
Allen. “It is sensitive to heat and is destroyed while cooking, but it doesn‟t take many bacteria to
make a human sick. The mortality rate from the gastrointestinal illness is very low, but a
Campylobacter infection has other consequences.”

“Twenty percent of people who have Guillain-Barrè syndrome have had a Campylobacter
infection,” said Allen. Guillain-Barrè syndrome is a neurological disease in which the immune
system destroys nerve cells.

Campylobacter‟s infection strategy is suspected of causing the problem. When the bacterium
infects a human, it makes proteins that mimic those of the host cell to hide from the immune
system. Antibodies developed to destroy the mimic proteins may attack and damage host cells as
well. “There is a great deal to know about how Campylobacter interacts with the host,” said
Allen. ”Why does it make humans sick while chickens don‟t react?”

To answer that question, researchers at VIDO are examining how the bacteria infect the host cell.
Once that is better understood, Allen‟s team will create a vaccine to encourage the chicken‟s
immune system to destroy the harmful strains of Campylobacter.

Unfortunately, the bacteria‟s erratic genetic code makes this a difficult task. The genes that
allow the bacteria to infect human cells have hypervariable, or constantly changing, DNA.
Hypervariable DNA causes the bacterial cell to „stutter‟ and make frequent mistakes when
making new copies of its DNA. These mistakes cause the new cell to have different
characteristics than the parent cell.

The constantly changing genetic landscape makes it difficult for researchers to create a vaccine
that will consistently target and eliminate harmful strains of Campylobacter. “We have learned
from E.coli 0157 that until you understand the host interactions with the bacterial cells, you can‟t
make a successful vaccine,” said Allen.

The poultry industry is motivated to gain that understanding and reduce the risk of harm from
their product. “Producers are aware of it because of food safety issues,” said Allen. Some
European producers are marketing certified Campylobacter- and Salmonella-free meat to address
their customers‟ food safety concerns.

The US government is currently monitoring levels of bacteria on meat products and is expected
to set regulatory limits in the near future. It is anticipated that the Canadian government will
follow suit.
“This is the new touch point for consumers,” said Allen. “The industry can make gains or can be
at risk.” If prevention is worth a pound of cure, one vaccine could save the poultry industry
another economically painful bout with a food pathogen.

For further information, contact Eileen Dent at eileendent@sympatic.ca




About The Town….People
      Dr. Marianne Greer, the former Saskatchewan Drug Research Institute (SDRI)
       Director, retired May 1, 2004. Sheila Anderson will serve as Acting Director and Anita
       Mack will serve as Acting Finance Director until a new Director is appointed.
      Dr. Lorne Babiuk, Director of the Vaccine and Infectious Disease Organization, was
       presented the Saskatchewan Order of Merit on January 26, 2004.
      Peter McCann, President of Brighton BioConsulting and Chair of the Board of Directors
       for the Biotechnology Human Resources Council (BHRC), was recognized for his
       contributions for Advancing the Benefits of Biotechnology for Canadians at the
       BIOTECanada Awards Luncheon, April 29-30, 2004.
      Dr. Malcolm Devine, the current Head of Technology Identification, Assessment and
       Acquisition for Bayer CropScience, was appointed Director, Research Programs at the
       Nation Research Council‟s Plant Biotechnology Institute.
      Dr. Graham Scoles will be Acting Dean of the College of Agriculture, University of
       Saskatchewan (U of S) while Dr. Ernie Barber is away on sabbatical.
      Brendan Fox was named President & CEO of Pyxis Genomics Inc. succeeding Dr.
       Lawrence Schook who will become the Executive Vice President & COO.
      Dr. Jo-Anne Dillon, current Director of the Centre for Research in Biopharmaceuticals
       and Biotechnology at the University of Ottawa, will replace Dr. Ken Coates in the
       position of Dean of Arts and Science at the U of S.
      Dr. Karen Chad, Professor of Kinesiology at the University of Saskatchewan, was
       appointed Acting Associate Vice-President Research for the U of S.
      Vishvajit Singh of Markham, ON and Jenny Wang of Toronto, ON were selected from
       the National Biology Training Camp held at the U of S to represent Canada at the
       International Biology Olympiad (IBO) in Brisbane, Australia in July 2004.
      Kimberly Richards, a grade 9 student at Walter Murray Collegiate, took top prize at the
       Saskatoon Region Aventis Biotech Challenge, as well as third prize at the National
       Aventis Biotech Challenge.
      MCN Bioproducts Inc., was named winner of the third annual Innovation Place-
       Industry Liaison Office Award of Innovation, May 2004.
      Dr. Brian Rossnagel, Professor at the College of Agriculture, U of S, was presented an
       award for Distinction in Extension and Public Service at the U of S.
    Dr. Ron Depauw, Cereals Section Head for Agriculture and Agri-Food Canada‟s Swift
     Current Research Centre, received the Order of Canada for his work in wheat breeding on
     May 14, 2004.
    Dr. Kutty Kartha, Director General NRC Plant Biotechnology Institute, will be awarded
     the PIPSC Gold Medal award June 15, 2003.
    John Buchan, Bio-Products Coordinator, has rejoined the Crop Development Branch to
     lead a team focused on the identification of bio-product opportunities in Saskatchewan,
     and to develop strategies for addressing these opportunities.


About The Town….Finance
    The Canadian Light Source (CLS) received $37 Million in funding this spring - $18
     Million from the Canada Foundation for Innovation (CFI), $16 Million from the Natural
     Sciences and Engineering Research Council (NSERC), and $3 Million from Western
     Economic Diversification. The funds will be used in part to open five new beamlines
     bringing the total to 12. For more information visit: http://www.lightsource.ca
    $19.2 Million was awarded to the University of Saskatchewan by the Canada Foundation
     for Innovation (CFI) to build an International Vaccine Centre (INTERVAC). The facility
     will be a collaboration between the Vaccine and Infectious Disease Organization, the
     College of Medicine, and the Western College of Veterinary Medicine. For more
     information visit: http://www.usask.ca/research
    Dr. Soledade Pedras, University of Saskatchewan Chemistry Professor, was awarded a
     $400,000 Accelerator Grant for Exceptional New Opportunities from the Natural
     Sciences and Engineering Research Council (NSERC) to explore a new approach to
     control white rust in canola. For more information visit: http://www.usask.ca/events/news/articles
    Agrisoma Biosciences Inc. secured financing to advance the development of its
     chromosome-based delivery and expression platform in plants. Investors include
     Canadian Medical Discoveries Fund Inc., the Business Development Bank of Canada,
     and other private individuals. Financial terms of the deal were not disclosed.
    Dr. Sylvia van den Hurk, Vaccine and Infectious Disease Organization, was awarded
     $345,280 in funding over four years from the Canadian Institutes of Health Research
     (CIHR) towards the design of a vaccine to protect infants against respiratory syncytial
     virus. For more information visit: http://www.usask.ca/events/news/articles
    The 2004 Federal Budget is providing $170 Million for the building of research
     foundations. Genome Canada will receive $60 million of those funds for university and
     industry research in proteomics and genomics. An additional $200 Million has been
     committed to the Sustainable Development Technology Canada (SDTC) to support
     environmental technologies, as well as $270 Million for venture capitol financing by the
     Business Development Bank of Canada (BDC) and the Farm Credit Corporation (FCC).
     For more information visit: http://www.fin.gc.ca/budget04/pamph/paecoe.htm
    The Government of Saskatchewan will contribute $2.64 Million towards 22 new
     agriculture and research projects through the Agriculture Development Fund (ADF). For
     more information visit: http://www.agr.gov.sk.ca/
About The Town….News
      Two new SARS vaccine candidates, developed in part by the Vaccine and Infectious
       Disease Organization, are being fast-tracked to testing. The project is a collaboration
       among VIDO, McMaster University, the British Columbia Centre for Disease Control
       (BCCDC) and the University of British Columbia (UBC). Vaccines typically require 10
       years to develop but it is hoped a successful SARS vaccine will be available in 5 years.
       For more information visit: http://www.usask.ca/events/news/articles
      The Canadian Light Source (CLS) achieved its environmental technology verification
       (ETV) certificate in April 2004. This certification will help the CLS market the
       synchrotron to non-academic users industries such as mining. For more information visit:
       http://www.usask.ca/events/news/articles
      Innovation Place, Saskatoon‟s research park, contributed $187 Million to the economy of
       Saskatoon, according to a recent study. In 2003, the Regina Research Park together with
       Innovation Place had a combined impact of $444 Million on the Saskatchewan economy.
   For more information visit: http://www.gov.sk.ca/newsrel/releases/2004/03/15-103.html




Ag-West Bio Inc. invests in 6 life science companies for
Saskatchewan

Ag-West Bio Inc. announced an investment of over a half million dollars in 6 local life science
companies – Clear-Green Environmental Inc., Pyxis Genomics Canada, Adnavance
Technologies, BioNatCom Inc., HeadsUp Plant Protectant, and Bio-ID Diagnostics.

“This broad range of investments serves to showcase this province‟s expanding bio-based
economy and Ag-West Bio‟s commitment to building a strong and vibrant life science industry
in Saskatchewan,” commented Ag-West Bio‟s President & CEO, Dr. Ashley O‟Sullivan at a
news conference held the end of April.

HeadsUpTM Plant Protectant

HeadsUpTM Plant Protectant technology, derived from a combination of plant extracts, has been
shown to stimulate natural disease defense mechanisms in plants. Four years of testing has
proven HeadsUpTM as a preventative treatment against bacterial spot in tomatoes and bacterial
scab and rhizoctonia in potatoes, as well as many other fungal, bacterial, and viral diseases of
plants.

“Comparative field trials show HeadsUpTM outperforming its competition not only in
effectiveness, but also in its cost advantage, ease of application, and user and environmental
friendliness,” said Joe Dutcheshen, founder of the HeadsUpTM technology. “The Ag-West Bio
funding will be used to achieve registration of this product and help bring it to market.”
Clear-Green Environmental Inc.

Another local company, Clear-Green Environmental, is focused on value-added processing of
organic wastes to produce biogas and natural fertilizers. Clear-Green operates an organic waste
processing plant outside of Cudworth, SK. The plant processes manure generated from a 1200
sow farrow-finish hog operation through a novel anaerobic digestion process.

“The investment from Ag-West Bio will allow us to develop our natural fertilizer production
technologies allowing us to extract the optimum value from our organic waste processing plant,”
commented Ben Voss, President and CEO of Clear-Green Environmental.

Pyxis Genomics Inc.

Antibiotics are frequently fed to animals at low doses to prevent disease. However, their use at
these sub-therapeutic levels has been banned in the EU and may soon be banned in other parts of
the world to prevent the development of resistant disease organisms. Pyxis Genomics is
researching and developing non-antibiotic feed additives to activate strengthen or enhance an
animal‟s immune system.

“These new feed additives will be used to fight disease at very specific times when risk of
infection is high- say at weaning or hatching,” said the President and CEO of Pyxis Genomics,
Dr. Brendan Fox. This technology will be tested in chicken models in conjunction with a lab at
the University of Saskatchewan.

BioNatCom Inc.

BioNatCom Inc, a company founded by a University of Saskatchewan researcher, Dr. Rui Wang,
and developed through the University of Saskatchewan Industrial Liaison Office (formerly the
UST office) is developing two natural health products. BuSY, the lead product for BioNatCom,
has been shown to be a highly effective, non-prescription treatment for erectile dysfunction.
Their second product, ExBau, effectively lowers blood pressure in hypertensive rat tests. The
investment from Ag-West Bio will be directed towards confirming product efficacy, dosage,
safety, and mechanism of action.

Adnavance Technologies Inc.

Adnavance Technologies is an early stage company developing metallic DNA (M-DNA) for
applications in both life science and nanotechnology industries. “M-DNA is created by
introducing metal atoms along a DNA helix. The metal atoms conduct electrons similar to a
metal wire,” explains Dr. Jeremy Lee, Director and founding scientist, “allowing for applications
as biosensors, DNA vaccines, and various nanotechnology markets, just to name a few
examples.”

Bio-ID Diagnostics Inc.
A local biotechnology company, Bio-ID Diagnostics, develops and licenses molecular biology
based platform technologies in clinical medicine and veterinary medicine, as well as
pharmaceutical, environmental and food industries.

Bio-ID's core technology, MultiGEN, is a novel modification of the Sanger method that allows
simultaneous identification of short stretches of unique DNA signature sequences from multiple
targets. This technology allows for the identification of the causative organism from a panel of
many other possible pathogens possibly causing the same clinical syndrome. Ag-West Bio‟s
investment will be used for validation of the technology leading to commercial sales.

Events
2004
June 6-9            BIO 2004, San Francisco, CA USA
                    http://www.bio.org/events/2004/

June 13-16          Finding Common International Goals, NABC 16, Guelph, ON Canada
                    http://www.uoguelph.ca/research/NABC/index.shtml
July 7-10           Canadian Seed Growers Association 100th Anniversary, Ottawa, ON Canada
                    http://www.seedgrowers.ca
July 11-16          23rd World Buiatrics Congress, Quebec, QC Canada http://www.wbc2004.ca
July 16-17          International Intellectual Property Law Conference, Vancouver, BC Canada
                    http://www.law.uvic.ca
July 31 - Aug. 4    2004 Annual Meeting of the American Phytopathological Society, Anaheim,
                    CA USA http://www.apsnet.org
Aug. 29 - Sept. 1   2nd Canadian Plant genomics Workshop, Quebec, QC Canada
                    http://www.cpgw-acgp.ca/quebec2004/en/

September 12-15     ABIC 2004, Cologne, Germany http://www.abic2004.org

September 27-29     Bio China 2004, Beijing, China http://www.biochina.net.cn

October 6-8         BioContact Quebec, Quebec City, QC Canada http://www.biocontact.qc.ca
October 18-20       bioLOGIC USA 2004, Boston, MA USA
                    http://www.lifescienceworld.com/2004/bio_US/
Ag-West Bio Inc. Board of Directors

Chair: Jerome Konecsni, Vice President of Corporate Development, Bioriginal Food &
Science Corp.
Vice-Chair: Armand Lavoie, VP, Western Canada, Foragen Technology Ventures Inc.
Secretary-Treasurer: Bill Compton, Plant Manager, ERCO Worldwide
Dale Botting, Executive Manager, Saskatchewan Industry and Resources
Maryellen Carlson, Assistant Deputy Minister, Saskatchewan Agriculture, Food and Rural
Revitalization
Ian McPhadden, Producer
Mark Pickard, General Manager, InfraReady Products


Ag-West Bio Inc. Publications

Ag-West Bio offers several publications at no cost. Please fax your requests to: 306-975-1966, e-
mail: subscriptions@agwest.sk.ca, or visit: http://www.agwest.sk.ca

The AgBiotech Bulletin is produced by Ag-West Bio Inc.
Editor: Janice Tranberg, Communications Director, Ag-West Bio Inc.
101-111 Research Dr., Saskatoon, SK Canada S7N 3R2
Phone: 306-975-1939 Fax: 306-975-1966
Web site: http://www.agwest.sk.ca

Readers wishing to have their comments considered for inclusion are encouraged to submit less
than 500 words via e-mail to: bulletin@agwest.sk.ca
Include your name and contact information. We reserve the right to edit for length.
J. Tranberg, Editor

Funding assistance is provided by Saskatchewan Agriculture, Food and Rural Revitalization.

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:3
posted:12/2/2011
language:English
pages:12